- Location
accelerated approval
"-
Pfizer Said The Trial of Its Pneumonia Immunization in Adults Age 65
Feb 26, 2014NEW YORK, Feb. 25 (UPI) -- Pfizer Inc. in New York said the trial of its pneumonia immunization in adults age 65 and older against bacterial pneumonia achieved its goals. The Community-Acquired Pneumonia Immunization Trial in Adults, the ...
-
FDA Has Approved GlaxoSmithKline's Use of Mekinist in Combination with Tafinlar
Jan 13, 2014The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) use of Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF ...
Tags: FDA, Combination Drug
-
Pfizer Has Secured Regular Approval From The Us Food and Drug Administration (FDA)
Nov 25, 2013Pfizer has secured regular approval from the US Food and Drug Administration (FDA) for its Xalkori (crizotinib) capsules to treat patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). The approval was based on ...
-
Janssen Therapeutics Has Obtained Accelerated Approval From FDA for Sirturo Tablets
Jan 4, 2013Janssen Therapeutics has obtained accelerated approval from FDA for Sirturo (bedaquiline) tablets as part of combination therapy to treat adult patients with pulmonary multi-drug resistant tuberculosis (MDR-TB). The surrogate endpoint of ...
Tags: Janssen Therapeutics, accelerated approval, FDA, Sirturo tablets
-
FDA Granted Accelerated Approval to Talon Therapeutics' Marqibo
Dec 5, 2012The US Food and Drug Administration (FDA) has granted accelerated approval to Talon Therapeutics' Marqibo (vinCRIStine sulfate LIPOSOME injection). Marqibo, a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine ...
-
Teva Pharmaceutical Received US FDA Approval for Synribo Injection
Nov 28, 2012Teva Pharmaceutical has received US Food and Drug Administration(FDA)approval for Synribo injection to treat adult patients with chronic phase(CP)or accelerated phase(AP)chronic myeloid leukemia(CML)with resistance and/or intolerance to ...
Tags: Teva Synribo Injection, US FDA, Teva Pharmaceutical, chronic phase
-
Talon Therapeutics Has Reported Net Income for The Third Quarter
Nov 28, 2012Talon Therapeutics has reported a net income applicable to common stock of $29.76m, or $1.35 per share, for the third quarter ended 30 September 2012 compared to a net loss applicable to common stock of $1.71m, or $0.08 per share, for the ...
Tags: Marqibo, Talon launch, strategic transaction